150 related articles for article (PubMed ID: 23932360)
1. Identification of fragments targeting an alternative pocket on HIV-1 gp41 by NMR screening and similarity searching.
Chu S; Gochin M
Bioorg Med Chem Lett; 2013 Sep; 23(18):5114-8. PubMed ID: 23932360
[TBL] [Abstract][Full Text] [Related]
2. The Tryptophan-Rich Motif of HIV-1 gp41 Can Interact with the N-Terminal Deep Pocket Site: New Insights into the Structure and Function of gp41 and Its Inhibitors.
Zhu Y; Ding X; Yu D; Chong H; He Y
J Virol; 2019 Dec; 94(1):. PubMed ID: 31619552
[TBL] [Abstract][Full Text] [Related]
3. Paramagnetic relaxation assisted docking of a small indole compound in the HIV-1 gp41 hydrophobic pocket.
Gochin M; Zhou G; Phillips AH
ACS Chem Biol; 2011 Mar; 6(3):267-74. PubMed ID: 21155611
[TBL] [Abstract][Full Text] [Related]
4. NMR second site screening for structure determination of ligands bound in the hydrophobic pocket of HIV-1 gp41.
Balogh E; Wu D; Zhou G; Gochin M
J Am Chem Soc; 2009 Mar; 131(8):2821-3. PubMed ID: 19206471
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of ligand-based NMR screening methods to characterize small molecule binding to HIV-1 glycoprotein-41.
Chu S; Zhou G; Gochin M
Org Biomol Chem; 2017 Jun; 15(24):5210-5219. PubMed ID: 28590477
[TBL] [Abstract][Full Text] [Related]
6. Non-peptide entry inhibitors of HIV-1 that target the gp41 coiled coil pocket.
Stewart KD; Huth JR; Ng TI; McDaniel K; Hutchinson RN; Stoll VS; Mendoza RR; Matayoshi ED; Carrick R; Mo H; Severin J; Walter K; Richardson PL; Barrett LW; Meadows R; Anderson S; Kohlbrenner W; Maring C; Kempf DJ; Molla A; Olejniczak ET
Bioorg Med Chem Lett; 2010 Jan; 20(2):612-7. PubMed ID: 20004576
[TBL] [Abstract][Full Text] [Related]
7. Interactions of HIV-1 inhibitory peptide T20 with the gp41 N-HR coiled coil.
Champagne K; Shishido A; Root MJ
J Biol Chem; 2009 Feb; 284(6):3619-27. PubMed ID: 19073602
[TBL] [Abstract][Full Text] [Related]
8. Creating an Artificial Tail Anchor as a Novel Strategy To Enhance the Potency of Peptide-Based HIV Fusion Inhibitors.
Su S; Zhu Y; Ye S; Qi Q; Xia S; Ma Z; Yu F; Wang Q; Zhang R; Jiang S; Lu L
J Virol; 2017 Jan; 91(1):. PubMed ID: 27795416
[TBL] [Abstract][Full Text] [Related]
9. ADS-J1 inhibits human immunodeficiency virus type 1 entry by interacting with the gp41 pocket region and blocking fusion-active gp41 core formation.
Wang H; Qi Z; Guo A; Mao Q; Lu H; An X; Xia C; Li X; Debnath AK; Wu S; Liu S; Jiang S
Antimicrob Agents Chemother; 2009 Dec; 53(12):4987-98. PubMed ID: 19786602
[TBL] [Abstract][Full Text] [Related]
10. Identification of a human protein-derived HIV-1 fusion inhibitor targeting the gp41 fusion core structure.
Chao L; Lu L; Yang H; Zhu Y; Li Y; Wang Q; Yu X; Jiang S; Chen YH
PLoS One; 2013; 8(5):e66156. PubMed ID: 23741527
[TBL] [Abstract][Full Text] [Related]
11. Inhibiting HIV-1 entry: discovery of D-peptide inhibitors that target the gp41 coiled-coil pocket.
Eckert DM; Malashkevich VN; Hong LH; Carr PA; Kim PS
Cell; 1999 Oct; 99(1):103-15. PubMed ID: 10520998
[TBL] [Abstract][Full Text] [Related]
12. Stable extended human immunodeficiency virus type 1 gp41 coiled coil as an effective target in an assay for high-affinity fusion inhibitors.
Cai L; Balogh E; Gochin M
Antimicrob Agents Chemother; 2009 Jun; 53(6):2444-9. PubMed ID: 19364877
[TBL] [Abstract][Full Text] [Related]
13. Conserved residues in the coiled-coil pocket of human immunodeficiency virus type 1 gp41 are essential for viral replication and interhelical interaction.
Mo H; Konstantinidis AK; Stewart KD; Dekhtyar T; Ng T; Swift K; Matayoshi ED; Kati W; Kohlbrenner W; Molla A
Virology; 2004 Nov; 329(2):319-27. PubMed ID: 15518811
[TBL] [Abstract][Full Text] [Related]
14. Identification and characterization of a subpocket on the N-trimer of HIV-1 Gp41: implication for viral entry and drug target.
Qiu Z; Chong H; Yao X; Su Y; Cui S; He Y
AIDS; 2015 Jun; 29(9):1015-24. PubMed ID: 26125136
[TBL] [Abstract][Full Text] [Related]
15. A novel fluorescence intensity screening assay identifies new low-molecular-weight inhibitors of the gp41 coiled-coil domain of human immunodeficiency virus type 1.
Cai L; Gochin M
Antimicrob Agents Chemother; 2007 Jul; 51(7):2388-95. PubMed ID: 17452484
[TBL] [Abstract][Full Text] [Related]
16. Probing Vulnerability of the gp41 C-Terminal Heptad Repeat as Target for Miniprotein HIV Inhibitors.
Jurado S; Moog C; Cano-Muñoz M; Schmidt S; Laumond G; Ruocco V; Standoli S; Polo-Megías D; Conejero-Lara F; Morel B
J Mol Biol; 2020 Sep; 432(20):5577-5592. PubMed ID: 32822695
[TBL] [Abstract][Full Text] [Related]
17. Design of a novel peptide inhibitor of HIV fusion that disrupts the internal trimeric coiled-coil of gp41.
Bewley CA; Louis JM; Ghirlando R; Clore GM
J Biol Chem; 2002 Apr; 277(16):14238-45. PubMed ID: 11859089
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of HIV-1 Resistance to Short-Peptide Fusion Inhibitors Targeting the Gp41 Pocket.
Su Y; Chong H; Qiu Z; Xiong S; He Y
J Virol; 2015 Jun; 89(11):5801-11. PubMed ID: 25787278
[TBL] [Abstract][Full Text] [Related]
19. Peptide and non-peptide HIV fusion inhibitors.
Jiang S; Zhao Q; Debnath AK
Curr Pharm Des; 2002; 8(8):563-80. PubMed ID: 11945159
[TBL] [Abstract][Full Text] [Related]
20. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but non-neutralizing antibodies also bind to NHR mimetics.
Nelson JD; Kinkead H; Brunel FM; Leaman D; Jensen R; Louis JM; Maruyama T; Bewley CA; Bowdish K; Clore GM; Dawson PE; Frederickson S; Mage RG; Richman DD; Burton DR; Zwick MB
Virology; 2008 Jul; 377(1):170-83. PubMed ID: 18499210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
